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Breast cancer is the most common malignant disease of females. Overall, one woman in every nine will get breast cancer at some
time in her life. Epidemiological studies have indicated that alcohol consumption has most consistently been associated with breast
cancer risk. However, the mechanism of alcohol-associated breast cancer remains to be addressed. Little is known about the effects
of alcohol consumption on Brf1 (TFIIIB-related factor 1) expression and RNA Pol III gene (RNA polymerase III-dependent gene)
transcription, which are responsible for protein synthesis and tightly linked to cell proliferation, cell transformation, and tumor
development. Emerging evidences have indicated that alcohol induces deregulation of Brf1 and Pol III genes to cause the
alterations of cell phenotypes and tumor formation. In this paper, we summarize the progresses regarding alcohol-caused
increase in the expression of Brf1 and Pol III genes and analysis of its molecular mechanism of breast cancer. As the earlier and
accurate diagnosis approach of breast cancer is not available yet, exploring the molecular mechanism and identifying the
biomarker of alcohol-associated breast cancer are especially important. Recent studies have demonstrated that Brf1 is
overexpressed in most ER+ (estrogen receptor positive) cases of breast cancer and the change in cellular levels of Brf1 reflects
the therapeutic efficacy and prognosis of this disease. It suggests that Brf1 may be a potential diagnosis biomarker and a
therapeutic target of alcohol-associated breast cancer.
1. Introduction
Alcohol intake is consistently associated with an increased
risk of breast cancer [1–4]. Alcohol is known to promote
mammary tumorigenesis [5–7]. Alcohol consumption is
associated with ER+ (estrogen receptor positive) cases of
breast cancer much more than with ER- cases of this disease
[8–10]. Although the exact mechanism by which alcohol
causes breast cancer is still unclear, alcohol consumption is
thought to induce breast carcinogenesis through various
mechanisms, such as the perturbation of estrogen metabolism
and response, mutagenesis by the ethanol metabolite acetalde-
hyde, and oxidative damage, as well as by affecting the one-
carbon metabolic pathways through reduced folic acid intake
and use [11]. Previous studies have shown that chronic alcohol
consumption results in the production of acetaldehyde and
induction of CYP2E1. Acetaldehyde is a by-product of alcohol
metabolism catalyzed by ADH (alcohol dehydrogenase),
which has direct mutagenic and carcinogenic effects in vitro
and in vivo studies [12]. CYP2E1 is associated with the release
of ROS (reactive oxygen species) and conversion of procarci-
nogens to carcinogens. Alcohol exposure increases cellular
production of ROS and induces cellular stress, resulting in tis-
sue injury and ALD (alcoholic liver disease).
However, little is known about the role of alcohol in Brf1
(TFIIIB-related factor 1) expression and Pol III gene (RNA
polymerase III-dependent gene) transcription during breast
tumor development. Pol III genes are responsible for protein
synthesis and tightly linked to cell proliferation, cell trans-
formation, and cancer development. RNA polymerase III is
responsible for the synthesis of a variety of small untrans-
lated RNAs, including tRNAs and 5S rRNA [12]. Brf1 is a
subunit of the TFIIIB complex of Pol III gene transcription
machinery. Brf1 specifically regulates tRNAs and 5S rRNA
transcription. The PNCs (perinucleolar compartments) are
dependent on the continuation of RNA Pol III gene tran-
scription and more prevalent in cancer cells than in normal
cells [13]. PNC prevalence significantly correlates with the
progression of breast cancer [14]. Accumulation of Pol III
gene transcripts around the nucleolus is especially evident
in transformed cells [15]. Consistent with the idea that a
high translational capacity is necessary for rapid growth
and proliferation of tumor cells, Pol III gene transcripts have
been found to be increased in human cancers [10, 16, 17].
Furthermore, expression of the Pol III gene, BC200, was ele-
vated in breast squamous cell carcinoma tissues [18]. Our
studies using both cell culture models and animal models
have revealed that alcohol induces transcription of tRNALeu
and 5S rRNA [19, 20]. This induction in mice fed with alco-
hol is associated with tumor development [19]. Alcohol-
induced tRNA and 5S rRNA transcription in a breast cancer
cell line is in an ERα-dependent manner [20]. These evi-
dences support the idea that ERα may mediate the modula-
tion of alcohol-induced Brf1 expression and Pol III gene
transcription in breast cells.
Genome-wide studies have demonstrated that many
RNA Pol II transcription factors are associated with RNA
Pol III transcribed genes and overlap the occupancy of
RNA Pol III [21]. Initial studies suggest that tRNAs are dif-
ferentially expressed in a tissue-specific manner and that
induction of RNA Pol III-dependent transcription may not
uniformly increase all tRNA isoacceptors [22]. It implies that
the differences of Pol III gene transcription levels match the
diversities in various physiological and pathological condi-
tions. The transcription machinery of tRNA genes is com-
posed of RNA Pol III, TFIIIB, and TFIIIC complexes to
control tRNA transcription, whereas, the 5S rRNA gene tran-
scription machinery consists with the complexes of RNA Pol
III, TFIIIB, TFIIIC, and TFIIIA. The complex of TFIIIB con-
sists of TBP and its associated factors, Brf1 (or Brf2) and
Bdp1. Brf1 and Bdp1 are specifically utilized in the Pol III
gene transcription process. TBP is required for transcription
by all three nuclear polymerases, Pol I, II, and III, in gene
transcription [23]. The tumor suppressors, BRCA1, p53,
pRb, and PTEN, repress, whereas oncogenes, such as Ras,
c-Jun, c-Myc, and c-Fos, increase Pol III gene transcription
[24–26] (Figure 1). An increase in TBP levels to induce Pol
III gene transcription is required for its transforming func-
tion [27–29]. Studies have demonstrated that change in
TBP expression is able to alter the cellular level of Bdp1,
but not Brf1 [30]. It suggests that Brf1 is more specific and
critically important in the regulation of tRNA and 5S rRNA
genes. A recent study indicates that alcohol-induced TBP
transcription is not significantly associated with ERα expres-
sion in ER+ breast cancer cells [20]. In contrast, alteration of
alcohol-induced ERα expression significantly changes cellu-
lar levels of Brf1 in these cells [20]. This implies that this
TFIIIB subunit, Brf1, may be involved in the ER-mediated
induction of Pol III genes caused by alcohol. In the review,
we will mainly focus on the role of alcohol-induced changes
in Brf1 expression and deregulation of Pol III genes.
2. Alcohol-Caused Alteration of Brf1 Expression
and Breast Cancer
In terms of the difference in regulation regions of RNA Pol
III genes, these genes are divided into three types. Type I of
Pol III genes is 5S rRNAs, and Type II of the genes is tRNAs,
whereas Type III is composed of other small Pol III genes
except type I and type 2 of these genes. Brf1 and Brf2
(TFIIB-related factor 2) are subunits of TFIIIB. Brf1 takes
part in the regulation of Type 1 (5S rRNAs) and Type 2
(tRNAs) Pol III gene transcription, whereas Brf2 mainly
modulates the transcription of Type III genes, such as U6,
7SL, and 7SK genes, and other small RNAs. As 5S rRNA
and tRNAs function protein synthesis, they are required to
cell growth, cell transformation, and tumor development.
Brf1 gene IDs of human, mouse, and rat are 2972, 72308,
and 299347, respectively. Human Brf1 gene (ID: 2972) pri-
marily codes a 90 kD protein. At the review, we primarily
focus on the discussions of abnormal Brf1 expression in the
cases of human breast cancer and alcohol-induced Brf1
expression in breast cancer cells.
2.1. Abnormal Expression of Brf1 and Its Significance in
Breast Cancer. As mentioned above, Brf1 specifically regu-
lates transcription of tRNAs and 5S rRNA genes, while the
deregulation of the Pol III genes is tightly linked to cell trans-
formation and tumor development. This suggests that Brf1
plays a critically important role in breast cancer. However,
the status of Brf1 expression in patients of breast cancer has
been determined until recently. The studies report that,
for the first time, 218 samples of human breast cancer have
been collected to measure the levels of Brf1 expression by
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Figure 1: The alteration of the TFIIIB complex of transcription
machinery. TFIIIB is a complex of the transcription machinery of
RNA Pol III genes; TFIIIB includes Brf1, Bdp1, and TBP.
Oncogenic proteins, such as c-Jun, c-Myc, Ras, and c-Fos activate
TFIIIB to enhance RNA Pol III gene transcription, resulting in
tumorigenesis. In contrast, tumor suppressors, such as BRCA1,
PTEN, p53, and pRb, inactivate its activity to decrease the
transcription of Pol III genes, leading to repression of tumor
development.
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immunohistochemistry method. 102 of 218 cases (46.8%)
display strong Brf1 staining in lesion tissues, which is classi-
fied in the high Brf1 expression group [10]. The other 116
cases (53.2%) of breast carcinoma include moderate, weak,
or negative staining of Brf1 in the lesion tissues, which is clas-
sified as the low Brf1 expression group [10]. The staining sig-
nals of Brf1 in most of the breast cancer cases primarily
accumulate in the nucleus, while its localization in the cyto-
plasm is only 3.7% (8/218) [10]. The most clinically patho-
logical characteristic of 218 cases is not the significant
correlation between Brf1 expression and other clinic patho-
logical features, such as patient age, pausimenia, histological
type, clinical stage, tumor size, lymph node, and metastasis
[10]. In contrast, there is a significant correlation between
high Brf1 expression and high ER expression (p = 0:012),
high PR expression (p = 0:035) or non-triple-negative status
(p = 0:012), but not Her2 expression (p = 0:357) [10]. These
studies reveal that the levels of Brf1 expression of the human
breast cancer are associated with their hormone statuses. The
results are consistent with an early study, which demon-
strates that ERα mediates alcohol-induced Brf1 expression
[20]. More interestingly, the OS (overall survival) times of
the patients with low Brf1 expression (118:7 ± 5:4 months,
n = 116) are significantly shorter than with the cases of high
Brf1 expression (137:5 ± 4:4 months, n = 102, p = 0:004)
[10]. Furthermore, the DFS (disease-free survival) periods
in the high Brf1 expression group (135:3 ± 5:0 months) are
markedly longer than those in the low Brf1 expression group
(112:8 ± 6:4months, p = 0:004) [10]. Therefore, these studies
show that patients with high Brf1 expression have better
prognosis after hormone therapy. It looks strange, as high
Brf1 expression in cancer patients should possess short sur-
vival times usually [17].
Approximately 80% cases of breast cancer are ER+ [4, 5,
31]. The ER+ patients were treated by hormone therapy after
they were diagnosed as breast cancer and performed surgery
resection, whereas a preferred drug of hormone therapy is
Tam (tamoxifen), which is an antagonist of the estrogen
receptor in breast tissue and has been widely used for the
treatment for both early and advanced ER+ breast cancers
in women [32]. We have demonstrated that high expression
of Brf1 in hepatocellular carcinoma cases displays short OS
period [17]. We also found the trend that the patients with
high Brf1 expression reveal short OS period in other cancers
(unpublished). More interestingly, our early studies have
found that Tam significantly inhibits the induction of Brf1
caused by alcohol in ER+ breast cancer cells [33]. As Tam
is able to repress Brf1 expression, the cellular levels of Brf1
in the ER+ patients are actually at low levels during hormone
treatment. This explains why high Brf1 expression has longer
survival periods in the ER+ cases than ER- cases with the dis-
ease. It suggests that cellular levels of Brf1 are not only as a
diagnosis marker but also as an indicator of prognosis under
hormone treatment.
2.2. Alcohol Increases Brf1 Expression to Promote Breast
Tumor Development. Emerging evinces indicate that alcohol
consumption is an established risk factor for breast cancer
[1–4]. The relative increase in risk ranges from 5 to 10%
(~1 drink/10 grams/day) to 40-50% (~3 drinks/day) [34, 35].
Studies have demonstrated that alcohol feeding prompted
mammary tumor formation in mice [36, 37]. Mechanism
analysis indicates that alcohol-promoted breast cancer
development may be through its effect on the expression of
aromatase and PPAR-γ with resulting increases in estrogen
(ER ligand) levels [38, 39]. However, Brf1 overexpression
in human cases of breast cancer is a direct evidence [10].
Mechanism studies demonstrate that alcohol increases Brf1
expression in ER+ breast cancer cells [20]. Alcohol induces
transformation of nontumor breast cells, and it also increases
the rates of colony formation of human breast cancer
cells [20]. However, once knocking down Brf1 expression
by its siRNA, the rates of colony formation will be signif-
icantly reduced. This indicates that alcohol-increased Brf1
expression is critically important in cell transformation and
tumor development.
2.3. ERα and Runx2 Mediate Alcohol-Induced Brf1
Expression. Studies have demonstrated that alcohol increases
the activity of the ERE-Luc promoter in ER+ MCF-7 cells
[20] and alcohol intake enhances the transcriptional activ-
ity of ERα and activates the E2 signaling pathway (37.40).
Alcohol increases cellular levels of Brf1 in ER+ breast can-
cer cells [20]. This implies that ERα has potential to mediate
Brf1 expression. Studies support the idea that E2, a ligand of
ERα, augments cellular levels of Brf1 mRNA and proteins. In
contrast, ERα siRNA significantly represses Brf1 expression
in ER+ breast cancer cells [20]. The capacity of ERα in Brf1
expression is not for another subunit, TBP, of TFIIIB complex.
Runx2 (Runt-related transcription factor 2) is a compo-
nent of ERα downstream and is modulated by ERα. Runx2
is expressed in ER+ human breast cancer cell lines and partic-
ipates in mammary gland development. Studies have indi-
cated that Runx2 plays important roles in tumor cell
growth and migration, as wells as in bone metastasis of breast
cancer. However, it remains to be investigated whether
Runx2 mediates Brf1 expression. Recently, we have deter-
mined the role of Runx2 in Brf1 expression. The results indi-
cate that Runx2 is overexpressed in human biopsies of breast
cancer (unpublished). Alcohol enhances Runx2 expression in
ER+ breast cancer cell line, MCF-7. Repression of Runx2
decreases Brf1 expression (unpublished). ERα mediates
alcohol-induced Runx2 expression in the cells (unpublished).
Together, these studies demonstrate that Runx2 modulates
Brf1 expression through the ERα pathway induced by alco-
hol. Alcohol-increased Runx2 expression may play a crucial
role in alcohol-associated breast cancer development.
2.4. Alcohol Induces Signal Events Which Mediate Brf1
Expression. Brf1 is a phosphorylated protein. Plk1 (polo-like
kinase 1) phosphorylates Brf1 on serine 450 to directly pro-
mote tRNA and 5S rRNA transcription in cell interphase
[40]. This stimulatory modification is overridden at mitosis,
when elevated Plk1 activity causes Brf1 phosphorylation on
threonine 270, which prevents RNA polymerase III recruit-
ment to the transcription machinery [40]. Studies have indi-
cated that PKB (protein kinase B) phosphorylates Brf1 at
serine 92, resulting in binding to 14-3-3 and impairment of
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mRNA decay activity [41]. Further analysis reveals that an
additional regulatory site of Brf1 is at serine 203, which coop-
erates with its serine 92 in vivo [42]. Brf1 serine 203 is also
phosphorylated by PKB. Mutation of both serine 92 and
serine 203 to alanine uncouples Brf1 from PKB regulation,
leading to constitutive mRNA decay even in the presence
of stabilizing signals [42]. The deregulation of Pol III gene
transcription has been linked to cancer, whereas germline
mutations of genes encoding RNA polymerase III subunits
or tRNA processing factors cause neurogenetic disorders
in humans, such as hypomyelinating leukodystrophies
and pontocerebellar hypoplasia [43]. Studies indicate that
disease-causing mutations reduce Brf1 occupancy at tRNA
genes to decrease Pol III gene transcription and impair cell
growth [43].
Although PIK and PKB are able to phosphorylate Brf1
[40–42], our studies indicate that alcohol activates JNK1,
but not JNK2 [19], while JNK1 indeed mediates alcohol-
induced Brf1 expression in both hepatocellular carcinoma
and breast cancer cells [19, 20]. In the ER+ breast cancer cell
line, MCF-7, alcohol activates JNK1 and enhances ERα activ-
ity to elevate Brf1 expression [20]. The increase in Brf1 and
Pol III genes by alcohol in ER+ breast cancer cell lines is sig-
nificantly higher than those in ER- breast cancer cell lines
and nontumor breast cell lines [20]. This finding is consistent
with an early study, in which Brf1 expression in ER+ human
breast cancer cases is higher than that in ER- cases [44].
Interestingly, inhibition of JNK1 signaling by its chemical
inhibitor or siRNA significantly reduces ERα activity, result-
ing in the decrease in Brf1 expression [20]. In contrast,
enhancing JNK1 expression augments ERα activity to elevate
cellular levels of Brf1 [20]. Further analysis indicates that the
decrease in ERα attenuates alcohol-caused induction of Brf1
expression [20]. Together, these studies indicate that differ-
ent phosphorylation of Brf1 reveals various functions in Pol
III genes. Alcohol increases ERα activity to enhance Brf1
expression through the JNK1 pathway (Figure 2).
2.5. Alcohol Increases Expression of Brf1 Causing the
Alterations of Cellular Phenotypes. Studies have demonstrated
that carcinogens are able to increase Brf1 expression in cell
culture models. EGF (epidermal growth factor) stimulates
Brf1 expression in mouse epidermal cell line to augment the
rates of cell growth and cell transformation [45]. Repressing
Brf1 expression inhibits the EGF-stimulated cell transforma-
tion [45], whereas DEN (diethylnitrosamine), a potent chem-
ical hepatocarcinogen, has widely been used to induce HCC
(hepatocellular carcinoma) in rodents. DEN administration
caused HCC in 100% of male mice [46]. A study has indi-
cated that DEN dramatically elevates Brf1 expression in liver
cells [47]. DEN-induced cell proliferation is inhibited by
decreasing the cellular level of Brf1 [47]. These studies dem-
onstrate that carcinogens are indeed able to increase Brf1
expression [45, 47]. Alcohol has been classified as carcino-
genic to humans by the IACR (International Agency for
Research on Cancer) [31, 48, 49]. It implies that alcohol has
potential to increase Brf1 expression, resulting in alteration
of cellular phenotypes. Alcohol may be a good reagent to
study the mechanism of breast cell proliferation, cell trans-
formation, and tumor development.
Studies have demonstrated that alcohol dramatically
increases Brf1 expression in ER+ breast cancer cell lines
[20]. Recent studies further indicate that Brf1 is overex-
pressed in human HCC biopsies [17]; the high Brf1 expres-
sion of the HCC patients displays shorter survival times
[17]. This indicates that the abnormal expression of Brf1
links to human cancers and high Brf1 expression predicts
worse prognosis of HCC. Although alcohol significantly
enhances Brf1 expression in ER+ breast cancer cells, low dose
(25mM) of alcohol alone is hard to induce transformation of
nontumor breast cells (MCF-10A) [20], while the MCF-10A
cells treated with EGF are able to cause colony formation in
soft agar assay. But, the treatment of EGF plus alcohol signif-
icantly increases the rates of cell transformation [20]. How-
ever, once Brf1 expression is repressed in MCF-10A cells,
the rates are dramatically reduced in this condition. And also,
the rates of cell proliferation are enhanced under alcohol
treatment in both liver cells and breast cells [17, 20]. Inhibi-
tion of Brf1 expression decreases alcohol-caused rates of cell
growth. These studies demonstrate that alcohol-increased
Brf1 expression causes the changes in cell phenotypes.
The above studies indicate that carcinogens increase Brf1
expression in vitro and abnormal expression of Brf1 is asso-
ciated with human cancers, such as breast cancer and HCC
[10, 17]. Brf1 is overexpressed in human biopsies of liver
and breast cancer cases. These evidences support the idea
that abnormal expression of Brf1 is tightly linked to cell
transformation and breast cancer.
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Figure 2: The alcohol-induced modulation of Brf1 expression.
Alcohol increases Brf1 expression through two ways in breast
cells. One is that alcohol activates JNK1 and MSK1 to upregulate
Brf1 expression; another way is that alcohol activates JNK1 to
enhance ERα and Runx2 expression, leading to augmenting Brf1
expression. The two pathways increase RNA Pol III gene,
eventually resulting in cell proliferation and transformation and
mammary tumor development, while Tam inhibits ERα activity
and decreases the cellular level of Brf1.
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2.6. Epigenetic Regulation of Brf1 Expression by Alcohol-
Induced Histone H3 Phosphorylation. Gene expression is epi-
genetically regulated through DNAmethylation and covalent
chromatin modifications, such as phosphorylation (H3ph),
acetylation (H3ac), and methylation (H3me) of histone H3
and other histones. Emerging evidences suggest that histone
modifications, such as methylation, are a dynamic process
that modulates transcriptional activity in both normal and
tumor cells [50–54]. Histone modifications are the conse-
quence of a balance of the enzymes, which involve histone
modifications. Histone methylation is a result of a coordi-
nated interplay between histone lysine methyltransferases
[such as EZH2 (enhancer of zeste homolog 2)] and demethy-
lases [such as LSD (lysine-specific demethylase) or KDM
(lysine demethylase)] at specific gene promoters, thereby con-
tributing to normal development or occurring disease [52, 55].
Triple methylation of histone H3 lysine 27 (H3K27me2/3)
and lysine 9 (H3K9me3) is a hallmark of silenced chromatin
[56]. In contrast, triple methylation of histone H3 lysine 4
(H3K4me3) is an activating histone mark [57, 58]. Histone
H3 phosphorylation (H3ph) is mediated by protein kinase,
such JNK1 and MSK1, and phosphatases [59, 60], whereas
histone H3 acetylation is modulated by histone acetyltrans-
ferases and deacetylases, such as HDAC1 and HDAC2. We
have reported that H3ph at serine 10 and serine 28
increases Pol III gene transcription to cause cell transforma-
tion (46.48). Inhibition of the H3ph decreases Pol III gene
transcription and represses cell transformation (46.48).
However, increasing H3ph occupancy in the Brf1 promoter
reduces H3K27me3 binding to them, leading to the enhance-
ment of Pol III gene transcription (46.48). Previous studies
have demonstrated that MSK1 mediates H3ph [60]. Very
recent studies further indicate that alcohol activates MSK1
and induces H3ph (unpublished). Inhibition of MSK1 signal-
ing by its chemical inhibitor, SB-747651A, represses the
induction of Brf1 expression caused by alcohol (unpub-
lished). Together, the above studies show that alcohol
induces Brf1 expression through the JNK1-MSK1-H3ph-
ERα and Runx2 pathway to cause phenotypic alterations of
breast cells (Figure 3).
3. Deregulation of RNA Pol III Genes and
Breast Cancer
As mentioned above, RNA polymerase III transcribes a vari-
ety of untranslated RNAs and the Pol III gene products
include tRNAs, 5S rRNAs, 7SL RNA, 7SK RNA, and U6
RNA [61–63]. Since the tRNAs and 5S rRNAs control the
translational and growth capacity of cells and link to tumor
development [64, 65], it is especially important to explore
alcohol’s role in the deregulation of Pol III genes and tumor
development. An animal study has demonstrated that alco-
hol increases the transcription of Pol III genes [19]. The levels
of tRNA and 5S rRNA transcription in the liver tumor tissues
of HCV NS5A transgenic mice are much higher than that in
nontumor liver tissues [19]. Alcohol feeding of mice pro-
motes mammary tumorigenesis [36, 37]. Cell culture studies
have demonstrated that the transcription products of RNA
Pol III genes were elevated in both transformed and tumor
cells [19, 20, 29, 33, 66–69], while the inductions of Pol III
genes by alcohol in tumor cells were much higher than those
in nontumor cells [33]. Consistent with this idea, enhanced
Pol III gene transcription is required for oncogenic transfor-
mation of cells [19, 20, 29]. It suggests that alcohol-induced
deregulation of Pol III genes play a crucial role in cell trans-
formation and tumorigenesis [19, 20, 29, 33, 36, 37].
3.1. The Feature of Alcohol-Enhanced Transcription of Pol III
Genes in Breast Cells. Breast cancer has become the most
common cancer and leading cause of cancer mortality in
women in the United States [70]. In terms of the status of
ER expression, the patients of breast cancer were divided into
ER+ cases and ER- cases. Approximately 80% cases of human
breast cancers are ER+, and ~20% cases are ER- [2, 5, 6]. The
latter include the cases of ER-, PR-, and Her-, which are called
triple-negative breast cancer (TNBC). Clinical studies indicate
that ER+ cases of breast cancer have good prognosis after hor-
mone treatment, while ER- cases display worse prognosis.
As alcohol intake is associated with ER+ cases of breast
cancer much more than with ER- cases of this disease
[8, 9], the mechanism analysis of alcohol-associated breast
cancer indicates that cellular levels of Pol III gene tran-
scription are significantly different in ER- breast cell lines,
not ER- nontumor breast cell lines (MCF-10A, MCF-10F,
and MCF12A) or ER- breast cancer cell lines (MDA-
MB235 and SKRB-3), from ER+ breast cancer cell lines
(MCF-7 and TDT477) [20]. Interestingly, the alcohol-
increased amounts of precursor tRNALeu and 5S rRNA tran-
script in ER+ breast cancer cells (MCF-7 and TDT477) are
dramatically higher than those in ER- cells (MCF-10A,
MCF12A, MDA-MB235, and SKRB-3) [10, 20, 66–69]. The
PP
PP
M
SK
1
PP
PP
M
SK
1
M
SK
1
P
M
SK
1
P PP
PP PP
P P PP PP PP
Brf1
expression 
Alcohol
Figure 3: Alcohol-induced histone H3 phosphorylation which
upregulates Brf1 expression. Alcohol induces activation of MSK1,
which binds to the sites of chromatin of the target genes.
Activated MSK1 mediates histone H3 phosphorylation (H3ph) to
cause chromatin remodeling at local, leading to increases in Brf1
transcription. P: the phosphorylation group.
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induction of Pol III genes caused by alcohol in ER+ MCF-7
cells is 5-6 higher than that in ER- breast cells (MCF-10A,
MCF-10F, MCF-12A, MDA-MB235, and SKRB-3). It sug-
gests that alcohol-induced deregulation of Pol III genes is in
an ER-dependent manner. The feature of alcohol-caused
deregulation of Pol III genes in ER+ breast cells is consistent
with that of alcohol intake which is associated with ER+ cases
of breast cancer.
3.2. Molecular Mechanism of Alcohol-Increased RNA Pol III
Gene Transcription in Breast Cancer Cells. As alcohol
enhances the activity of ERα and activates the E2 signaling
pathway in breast cells [37, 71], it suggests that ERα may be
involved in the modulation of alcohol-induced transcription
of Pol III genes. Alcohol treatment increases the activity of
the ERE-Luc promoter [20, 72]. E2, a ligand of ERα, elevates
3-fold of the ERE-Luc activity, while alcohol plus E2 pro-
duces 4.5-fold of its activity in ER+ breast cancer cells [20].
In addition, alcohol strongly increases the cellular levels of
ERαmRNA or protein [20]. These studies demonstrated that
alcohol indeed enhances ERα expression in ER+ breast can-
cer cells. To establish whether ERα expression affects Pol III
gene transcription, ER+ breast cancer cells (MCF-7) were
treated with alcohol. The results indicate that E2 alone ele-
vated (~2-fold) tRNALeu and 5S rRNA transcription, while
alcohol plus E2 produces 11-14-fold of the increase in the
transcription of Pol III genes [20]. However, inhibiting
expression of ERα by its siRNA reduces the levels of ERα
mRNA and protein and also decreases the transcription of
tRNALeu and 5S rRNA [20]. These studies support the con-
clusion that ERα modulates alcohol-induced transcription
of Pol III genes.
Tam is an estrogen receptor antagonist. Tam competi-
tively binds to ER in tumors and other tissue targets to inhibit
estrogen effects [32]. The traditional concept of Tam efficacy
in breast cancer therapy is known through the ERα pathway.
Recent studies demonstrate that Tam is able to directly
inhibit alcohol-induced transcription of Brf1 and Pol III
genes [33]. This function of Tam may explain its efficacy in
ER+ cases of breast cancer, but not TNBC cases. This new
finding provides the possibility that inhibition of Pol III gene
transcription may be a potential approach to repress alcohol-
promoted cell transformation and breast cancer development
and to elevate the efficacy in Tam-resistant cases of ER+
breast cancer.
In addition, very recent studies indicate that Runx2 is
overexpressed in human biopsies of breast cancer (unpub-
lished). Alcohol enhances Runx2 expression in ER+ breast
cancer cells. Repression of Runx2 decreases Brf1 expression
and Pol III gene transcription. Further analysis indicates that
Runx2 and Brf1 colocalize in the nucleus and they synergisti-
cally modulate Pol III gene transcription. Because ERαmedi-
ates alcohol-induced Runx2 expression in ER+ MCF-7 cells,
the above studies demonstrate that Runx2 modulates Brf1
expression and Pol III gene transcription through the ERα
pathway induced by alcohol.
3.3. Brf1 Plays a Critical Role in Alcohol-Induced
Deregulation of Pol III Genes. As Brf1 is a key transcription
factor to directly regulate Pol III gene activity, once the levels
of Brf1 are changed in any physiological and pathological
conditions, the cellular levels of tRNAs and 5S rRNAs would
be altered, resulting in changes in cellular phenotype or
occurrence of diseases, even tumor development. As men-
tioned above, these factors, such as signaling molecules (such
as JNK1 and MSK1), hormone receptor (such as ERα), tran-
scription factors (such as Runx2, BRCA1), epigenetic modifi-
cations (such as histone H3 phosphorylation), carcinogens
(such as alcohol, EGF, DEN), medicine (Tam), and others
[ [20, 31, 33, 66–69, 73] and (unpublished)], which impact
Brf1 expression, lead to deregulation of Pol III genes and
cause cell proliferation, cell transformation, and eventually
breast cancer development. The alcohol-induced deregula-
tion of RNA Pol III genes is a consequence of Brf1 expres-
sion change in ER+ breast cells. In terms of the feature of
Brf1 in breast tissue, it strongly implies that developing an
inhibitor to repress Brf1 expression may reach to the ther-
apeutic purpose of human breast cancer.
4. Summary and Prospects
Alcohol is a liquid diet and widely used as consumption
drink in daily life. Alcohol has been classed as a carcinogen
to human by IACR in 2011 [31, 48, 49]. Alcohol intake-
associated diseases have caused more and more attention. It
has especially shown solicitude for that alcohol consumption
is consistent with the risk of breast cancer in women. Studies
have demonstrated that Brf1 is overexpressed in ER+ cases of
breast cancer. High expression of Brf1 in ER+ cases of this
disease shows better prognosis under the hormone treat-
ment. Further studies indicate that a hormone drug, Tam,
is able to directly repress Brf1 expression, causing the reduc-
tion of Pol III gene transcription except Tam competitively
binding to ER. Mechanism studies have demonstrated that
ERα affects the TFIIIB subunit and Brf1 expression, but not
TBP, in breast cells. This feature of Brf1 in breast cancer pro-
vides a possibility to develop a new approach by inhibiting
Brf1 expression for therapy of the patients of breast cancer.
Brf1 is not only a therapeutic target of breast cancer but also
a biomarker of prognosis of the disease. In the future, more
and more attention should be immersed into the studies of
the Brf1 inhibitor as a novel approach of breast cancer ther-
apy. It will be of huge interest for both basic science and clin-
ical communities to investigate this mechanism of alcohol-
associated breast cancer and identify whether reducing Brf1
expression and Pol III gene transcription by direct or indirect
manners represses mammary tumor development.
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